Genmab A/S (NASDAQ:GMAB) Rating Reiterated by HC Wainwright

Genmab A/S (NASDAQ:GMAB)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a research report issued to clients and investors on Friday, Benzinga reports. They presently have a $50.00 target price on the stock. HC Wainwright’s price target would suggest a potential upside of 95.85% from the company’s previous close.

Several other equities research analysts have also issued reports on the stock. JPMorgan Chase & Co. reissued a “neutral” rating on shares of Genmab A/S in a research note on Tuesday, August 20th. Truist Financial lowered their target price on shares of Genmab A/S from $53.00 to $50.00 and set a “buy” rating on the stock in a research note on Monday, September 9th. BTIG Research increased their target price on shares of Genmab A/S from $46.00 to $47.00 and gave the stock a “buy” rating in a research note on Thursday, June 27th. Royal Bank of Canada raised shares of Genmab A/S from a “sector perform” rating to an “outperform” rating in a research note on Monday, July 15th. Finally, Morgan Stanley reaffirmed an “equal weight” rating and issued a $31.00 price target on shares of Genmab A/S in a research note on Wednesday, September 11th. Two investment analysts have rated the stock with a sell rating, three have assigned a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat, Genmab A/S has an average rating of “Hold” and a consensus target price of $45.20.

Genmab A/S Stock Performance

Shares of GMAB opened at $25.53 on Friday. The business’s 50-day moving average is $27.27 and its two-hundred day moving average is $27.99. The company has a market capitalization of $16.88 billion, a P/E ratio of 21.28, a P/E/G ratio of 0.81 and a beta of 0.99. Genmab A/S has a fifty-two week low of $24.53 and a fifty-two week high of $37.00.

Genmab A/S (NASDAQ:GMAB) last posted its earnings results on Thursday, August 8th. The company reported $0.22 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.29 by ($0.07). Genmab A/S had a return on equity of 17.48% and a net margin of 29.06%. The firm had revenue of $779.50 million for the quarter, compared to analysts’ expectations of $734.60 million. Analysts forecast that Genmab A/S will post 1.27 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of GMAB. DDD Partners LLC purchased a new position in Genmab A/S in the 2nd quarter worth approximately $8,860,000. Capital International Investors lifted its stake in Genmab A/S by 7.8% in the 1st quarter. Capital International Investors now owns 4,373,277 shares of the company’s stock worth $130,805,000 after purchasing an additional 315,355 shares in the last quarter. First Trust Advisors LP lifted its stake in Genmab A/S by 16.0% in the 4th quarter. First Trust Advisors LP now owns 1,270,095 shares of the company’s stock worth $40,440,000 after purchasing an additional 175,292 shares in the last quarter. Cubist Systematic Strategies LLC lifted its stake in Genmab A/S by 109.7% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 278,541 shares of the company’s stock worth $7,000,000 after purchasing an additional 145,689 shares in the last quarter. Finally, Renaissance Technologies LLC lifted its stake in Genmab A/S by 7.6% in the 2nd quarter. Renaissance Technologies LLC now owns 1,462,459 shares of the company’s stock worth $36,752,000 after purchasing an additional 103,859 shares in the last quarter. 7.07% of the stock is owned by hedge funds and other institutional investors.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.